US-based medical test developer Exosome Diagnostics has closed a $60m series B round featuring biotechnology company Qiagen.
Qiagen co-led the round’s $27m first tranche in 2014 alongside private equity firm Arcus Ventures. The first close also featured Tiger Partners, CD Ventures, Monashee Capital, NGN Capital and Forbion Capital Partners.
Exosome raised an extra $17.6m in September 2015 from Forbion, NGN, Arcus, CD and Tiger Management. Blue Ridge Capital participated in the final close, though further details concerning investors in the third tranche have not been revealed.
Founded in 2008, Exosome has developed diagnostics technology to gain molecular insight into life-threatening diseases such as cancer. The results from these tests can be used to offer personalised healthcare to patients.
The series B capital will support Exosome’s commercial diagnostics, regulatory and companion diagnostics divisions. The company also hopes to expand development and adapt its technology for conditions other than cancer, such as neurodegenerative diseases.
Exosome previously obtained $20m in series A capital in a 2010 round co-led by NGN and Forbion.